Wegovy Sees Uptick, But Novo Faces Investor Skepticism
The U.S. ban on copycat versions of Novo Nordisk's weight-loss drug Wegovy has resulted in early increased demand but investors want more evidence of growth before the ...
Read moreDetails
© 2025 Newsweek U.S. All rights reserved.
